India, June 11 -- Researchers at the University of Cambridge have achieved a major milestone in vaccine development by successfully testing an artificial intelligence (AI)-designed universal coronavirus vaccine in humans for the first time. Early results show that the vaccine is safe, well tolerated, and capable of generating immune responses against a broad range of coronaviruses.
The experimental vaccine was developed by scientists in partnership with DIOSynVax (DVX) Ltd, a biotechnology company spun out from the university. In a Phase 1 clinical trial involving 39 healthy volunteers, the vaccine caused no serious side effects, providing an encouraging first step toward broader coronavirus protection.
Unlike conventional vaccines, which...